Efficacy of FK463, a New Lipopeptide Antifungal Agent, in Mouse Models of Pulmonary Aspergillosis

作者：Satoru Matsumoto, Yoshimi Wakai, Toru Nakai, Kazuo Hatano, Tomoe Ushitani, Fumiaki Ikeda, Shuichi Tawara, Toshio Goto, Fumio Matsumoto, Shōgo Kuwahara · 发表于：Antimicrobial Agents and Chemotherapy · 年份：2000 · DOI：10.1128/aac.44.3.619-621.2000 · 被引用次数：89 · 研究领域：Antifungal resistance and susceptibility、Antimicrobial Peptides and Activities、Mycotoxins in Agriculture and Food

The efficacy of FK463, a novel water-soluble lipopeptide, was evaluated in mouse models of pulmonary aspergillosis and was compared with that of amphotericin B (AMPH-B). In the pulmonary aspergillosis models induced by intranasal inoculation, FK463 exhibited good efficacy, with 50% effective doses in the range of 0. 26 to 0.51 mg/kg of body weight; these values were comparable to those of AMPH-B. In an Aspergillus target organ assay with immunosuppressed mice, under conditions of constant plasma levels of FK463, using a subcutaneously implanted osmotic pressure pump, a significant reduction in viable fungal cells was observed at plasma FK463 levels of 0.55 to 0.80 microgram/ml or higher. We conclude that FK463 is highly effective in the treatment of pulmonary aspergillosis in this animal model. These results indicate that FK463 may be a potent parenterally administered antifungal agent for pulmonary aspergillosis.